Yichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma

Reuters

09 Jun

Yichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma

Yichang Hec Changjiang Pharmaceutical Co., Ltd. has released a joint announcement with Sunshine Lake Pharma Co., Ltd., providing a monthly update on the proposed merger by absorption. This transaction involves the privatization of Yichang Hec Changjiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. The companies are progressing with the fulfillment of a pre-condition necessary for the merger. Zhang Yingjun, Chairman of Sunshine Lake Pharma, and Tang Xinfa, Chairman of Yichang Hec Changjiang Pharmaceutical, signed off on the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. Ltd. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2542384371"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542384371\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542384371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542384371","market":"us","top_or_hot":-1,"title":"Yichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Yichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Yichang Hec Changjiang Pharmaceutical Co., Ltd. has released a joint announcement with Sunshine Lake Pharma Co., Ltd., providing a monthly update on the proposed merger by absorption. This transaction involves the privatization of Yichang Hec Changjiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. The companies are progressing with the fulfillment of a pre-condition necessary for the merger. Zhang Yingjun, Chairman of Sunshine Lake Pharma, and Tang Xinfa, Chairman of Yichang Hec Changjiang Pharmaceutical, signed off on the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. Ltd. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Yichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Yichang Hec Changjiang Pharmaceutical Co., Ltd. has released a joint announcement with Sunshine Lake Pharma Co., Ltd., providing a monthly update on the proposed merger by absorption. This transaction involves the privatization of Yichang Hec Changjiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. The companies are progressing with the fulfillment of a pre-condition necessary for the merger. Zhang Yingjun, Chairman of Sunshine Lake Pharma, and Tang Xinfa, Chairman of Yichang Hec Changjiang Pharmaceutical, signed off on the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. Ltd. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01558","symbol_name":"东阳光长江药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL4kKKM2:1","article_id":"2542384371","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542384371","pubTimestamp":1749470873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Yichang Hec Changjiang Pharmaceutical Co., Ltd. has released a joint announcement with Sunshine Lake Pharma Co., Ltd., providing a monthly update on the proposed merger by absorption. This transaction involves the privatization of Yichang Hec Changjiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. The companies are progressing with the fulfillment of a pre-condition necessary for the merger. Zhang Yingjun, Chairman of Sunshine Lake Pharma, and Tang Xinfa, Chairman of Yichang Hec Changjiang Pharmaceutical, signed off on the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. Ltd. published the original content used to generate this news brief on June 09, 2025, and is solel","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01558":"东阳光长江药业","BK1191":"制药","BK1515":"抗疫概念"},"translate_title":"宜昌东阳光长江药业每月提供与阳光湖药业拟议合并的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01558":0.9},"content_text":"Yichang HEC Changjiang Pharma Provides Monthly Update on Proposed Merger with Sunshine Lake Pharma\n    \n\n        Yichang Hec Changjiang Pharmaceutical Co., Ltd. has released a joint announcement with Sunshine Lake Pharma Co., Ltd., providing a monthly update on the proposed merger by absorption. This transaction involves the privatization of Yichang Hec Changjiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. The companies are progressing with the fulfillment of a pre-condition necessary for the merger. Zhang Yingjun, Chairman of Sunshine Lake Pharma, and Tang Xinfa, Chairman of Yichang Hec Changjiang Pharmaceutical, signed off on the announcement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. Ltd. published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}